Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by francois21on Dec 16, 2016 9:24am
322 Views
Post# 25609218

RE:RE:RE:RE:ProMetic: Time Is Up For This Biotech ProMotion Must Read|De

RE:RE:RE:RE:ProMetic: Time Is Up For This Biotech ProMotion Must Read|DeThis is a so call article by a shorter spreading false informations and rumors.

First saying that PLI give half of the economic of the plasminogen is simply false, it's only applied to PD1. Any other application (would healing or any off label indication is not in the Hematech deal)

Also saying that competitors past over that protein is simply funny. The competitors didn't past over, they can't extract on a commerical scale..... 

And saying that other fractionators extract the plasminogen as an impurity is totally absurb....

That lead to the second major lie, denying that the PPPS platform is more effective. On what base he said so: 

The core technology was acquired for less than $5M.

Maybe he should consider the number of years and R&D dollars spent to bring it to the actual level.

And it's already proven effective and bring to commercial scale up.....

This is plain and stupid demagogy, not more, not less.

Another example of the plain and stupid demagogy is the talking about a graveyard of failing pipeline. 

Well, if it's true that PLI did mentionned many coumpounds in the past, they were mentionned as discovery in pre clinical stage.

They are not yet push further in development simply for economic reason. This is not a failure.

PBI-1402 died simply because the FDA change the rules of approval for EPO alike molecules.

Saying that PBI-4050 will failed, is based simply on nothing.......

We can talk about the past, wich is nearly what seems to be true in this report, as for the missing target in revenues and missing promises. PLI is not perfect in everything.

However, starting talking about  Crystal research for a report made in 2005, trying to make a case about pumped stuff is truly funny. We are in 2016, 11 years later.

Maybe instead of talking about what happened 11 years ago, he should talk a little more about the next 12 months....

For the rest, trying to make a point by attacking the Hybridan-PLI relation, is simply showing how poor is his analysis.

But Seeking Alpha blogs are not at their first false report, Nobilis Healthcare have been also targeted by shorter that made plenty of false claims while they short the stock.

I wonder about the legality of such article....     









Bullboard Posts